Recent declines in U.S. overdose deaths offer a rare sign of progress in a public health crisis that has claimed hundreds of thousands of lives. But according to a new January 2026 report from the American Medical Association (AMA), the nation’s overdose epidemic is evolving faster in ways that require the healthcare system to adapt more quickly.
The report notes that recent provisional national estimates suggest annual overdose deaths have declined from roughly 110,000 in 2023 to approximately 75,000 by 2025. While encouraging, the AMA warns that the decline does not signal the end of the crisis. Instead, illicitly manufactured fentanyl continues to dominate the drug supply, and nearly 60% of overdose deaths now involve more than one substance, creating new clinical challenges for healthcare providers.
As overdose patterns shift, addiction specialists say treatment programs, insurers and policymakers will need to evolve as well.
Polysubstance Use Is Changing the Overdose Landscape
For much of the past decade, public attention has centered on opioids and fentanyl. While those drugs remain responsible for the majority of overdose deaths, today’s patients increasingly arrive with combinations of opioids, stimulants, benzodiazepines and other substances in their systems.
This trend, known as polysubstance use, can complicate every stage of care, from emergency overdose reversal to medical detoxification and long-term recovery planning.
Unlike opioid-only withdrawal, polysubstance withdrawal often presents with overlapping physical and psychiatric symptoms that require individualized treatment plans, close medical monitoring and clinicians experienced in managing multiple substance use disorders simultaneously.
The AMA suggests healthcare systems must increasingly address multiple substance use disorders simultaneously as polysubstance use becomes more common.
The Recovery Village has observed similar trends in its own research. In a nationwide survey of people with opioid use histories, 89% reported using another substance alongside opioids, underscoring how common polysubstance use has become among individuals with opioid use disorder.
Treatment Access Has Improved, but Significant Barriers Remain
The AMA report highlights one area of measurable progress: the widespread adoption of buprenorphine, one of the three FDA-approved medications for opioid use disorder (MOUD).
According to the report, annual buprenorphine prescriptions increased from approximately 1.4 million in 2012 to 15.4 million in 2024, reflecting broader acceptance of medication-assisted treatment and expanded prescribing authority.
Even so, the organization explains that medications remain significantly underused relative to the number of Americans living with opioid use disorder.
Among the barriers cited are:
- Prior authorization requirements imposed by insurers
- Coverage restrictions
- Persistent stigma surrounding medication treatment
- Limited provider participation in some communities
Extensive research has shown that medications such as buprenorphine and methadone reduce overdose deaths, improve treatment retention and support long-term recovery when combined with behavioral therapies.
The AMA is urging policymakers and insurers to eliminate prior authorization requirements for medications used to treat opioid use disorder, arguing that delays in treatment can increase the risk of overdose.
Modern Addiction Treatment Requires Greater Flexibility
As substance use becomes more complex, many addiction specialists emphasize the importance of treatment programs that can address multiple conditions simultaneously rather than focusing on a single drug.
Individuals experiencing opioid use disorder frequently present with co-occurring mental health conditions, stimulant use disorders or alcohol misuse. Successfully treating these patients often requires coordinated medical detoxification, medication-assisted treatment, behavioral therapies and ongoing psychiatric support.
The Recovery Village’s continuum of care reflects this integrated approach, offering medical detox, inpatient rehabilitation, partial hospitalization, intensive outpatient programs and outpatient services while incorporating medication-assisted treatment and care for co-occurring mental health disorders throughout recovery.
This comprehensive model becomes increasingly important as polysubstance use complicates treatment planning and recovery.
Policy Changes Could Shape the Next Phase of the Overdose Response
Beyond eliminating prior authorization requirements, the AMA is also calling for expanded access to methadone outside traditional opioid treatment programs and stronger enforcement of federal mental health parity laws.
The recommendations reflect a growing consensus among addiction medicine experts that regulatory barriers, not just clinical challenges, continue to limit access to lifesaving treatment.
Many public health experts believe the nation’s recent decline in overdose deaths demonstrates that prevention efforts, naloxone distribution and expanded treatment access are believed to have contributed to the recent declines in overdose deaths. However, they caution that sustaining this progress will require adapting to an increasingly unpredictable drug supply and ensuring evidence-based treatment remains accessible without unnecessary delays.
The Bottom Line
The latest AMA report suggests the overdose epidemic has entered a new phase. While recent provisional estimates point to a significant reduction in overdose deaths, fentanyl remains deeply embedded in the illicit drug supply, and polysubstance use has become a defining characteristic of today’s crisis.
For treatment providers, insurers and policymakers alike, the challenge is no longer simply expanding access to care—it is ensuring the healthcare system can respond to the growing complexity of addiction with integrated, evidence-based treatment that reflects how substance use disorders present today.
Interview an Expert
Do you need a subject matter expert to interview on this topic? Dr. Brian D. Barash, Chief Medical Officer at The Recovery Village is available. Call us at 407-304-9824 to schedule an interview or get more information.
